Thanks for the info and updates, Alan. I`m moving this thread to the `HCV News` section.
Freshhope said
Apr 29, 2013
Latest news from EASL over the weekend is that the Gilead all oral drugs seem to be very effective for Genotype 2 (up to 98%) but there's a strong relapse rate for Genotype 3 (63 % SVR for those without cirrhosis and only 37% for those with cirrhosis). They are also using the drug for Genotype 1 but it seems most effective with Peg-int. That will probably be the drug available first as an alternative to the current triple therapy. However, if a person is genotype 1 and can wait for one of the other oral drugs by the end of 2014 or get into a trial, that's probably the way to go. Most of these new oral combinations are showing 80+ percent effectiveness even for prior relapses and cirrhotics. However, just like with the Gilead drugs we need to wait for the full phase 3 data to see if the gains are short-term or have staying power. The AbbVie drugs as well as simprevir, faldaprevir and daclatasvir all seem to offer real promise for a short 12-24 week therapy with manageable side effects (mainly headache and fatigue). Some new trials are also dropping ribavirin and it's possible that there will be success without resorting to this drug as well (Which is toxic to red blood cells and causes rashes). Good news for the future!
Alan
-- Edited by Freshhope on Monday 29th of April 2013 03:56:53 AM
-- Edited by Freshhope on Tuesday 30th of April 2013 04:01:32 AM
Loopy Lisa said
Apr 29, 2013
Hi Alan,
Does that statistic apply for non cirrhotics with genotype 3? Now I'm wondering if I should even wait!
Bills said
Apr 29, 2013
Thanks so much Alan
As you can see anything I hear about Gilead / Brisol Meyers it catches my eye. I've relapsed 3 times before completion of any therapy I've been on.
I'm very anxious ( too anxious ) to do it again however no more Interferon / Riba I really do want to wait for the end of trials to do this again but can't help wanting to get this overwith. I really fear resitance to the drugs and getting my hopes up again as well
but thanks for helping me better understand whats been going on
Bill S
Freshhope said
Apr 28, 2013
Latest news from EASL over the weekend is that the Gilead all oral drugs seem to be very effective for Genotype 2 (up to 98% for those without cirrhosis) but there's a strong relapse rate for Genotype 3 (up to two-thirds of those with cirrhosis and GT 3). They are also using the drug for Genotype 1 but it seems most effective with Peg-int. That will probably be the drug available first as an alternative to the current triple therapy. However, if a person is genotype 1 and can wait for one of the other oral drugs by the end of 2014 or get into a trial, that's probably the way to go. Most of these new oral combinations are showing 80+ percent effectiveness even for prior relapses and cirrhotics. However, just like with the Gilead drugs we need to wait for the full phase 3 data to see if the gains are short-term or have staying power. The AbbVie drugs as well as faldaprevir and daclatasvir all seem to offer real promise for a short 12-24 week therapy with manageable side effects (mainly headache and fatigue). Some new trials are also dropping ribavirin and it's possible that there will be success without resorting to this drug as well (Which is toxic to red blood cells and causes rashes). Good news for the future!
Alan
-- Edited by Freshhope on Monday 29th of April 2013 03:56:53 AM
-- Edited by Freshhope on Monday 29th of April 2013 04:09:12 AM
Bills said
Apr 27, 2013
Thanks Alan
That is so encouraging Thanks for posting that
Bill S
Biggyb said
Apr 27, 2013
Thanks Alan, gives hope.
Loopy Lisa said
Apr 27, 2013
Thanks for posting, I would have treated straight away if it wasn't for the fact these drugs are nearly available. Roll on 2014! :D
Freshhope said
Apr 27, 2013
Correction, I believe Gilead will deliver in early 2014 if they get FDA approval.
Freshhope said
Apr 27, 2013
The new oral regimens seem to be doing well in further reports from EASL this week. Gilead looks like it will deliver to market in 2013 and be particularly effective for Genotypes 2 and 3. AbbVie reported impressive results Genotype I. 24 weeks post treatment the "cure" rate was 96%! The results for prior non-responders are also very good. However, I'm not sure when they will get approval. Bristol-Myers is close behind, although they have to do a few more trials.
Thanks for the info and updates, Alan. I`m moving this thread to the `HCV News` section.
Latest news from EASL over the weekend is that the Gilead all oral drugs seem to be very effective for Genotype 2 (up to 98%) but there's a strong relapse rate for Genotype 3 (63 % SVR for those without cirrhosis and only 37% for those with cirrhosis). They are also using the drug for Genotype 1 but it seems most effective with Peg-int. That will probably be the drug available first as an alternative to the current triple therapy. However, if a person is genotype 1 and can wait for one of the other oral drugs by the end of 2014 or get into a trial, that's probably the way to go. Most of these new oral combinations are showing 80+ percent effectiveness even for prior relapses and cirrhotics. However, just like with the Gilead drugs we need to wait for the full phase 3 data to see if the gains are short-term or have staying power. The AbbVie drugs as well as simprevir, faldaprevir and daclatasvir all seem to offer real promise for a short 12-24 week therapy with manageable side effects (mainly headache and fatigue). Some new trials are also dropping ribavirin and it's possible that there will be success without resorting to this drug as well (Which is toxic to red blood cells and causes rashes). Good news for the future!
Alan
-- Edited by Freshhope on Monday 29th of April 2013 03:56:53 AM
-- Edited by Freshhope on Tuesday 30th of April 2013 04:01:32 AM
Hi Alan,
Does that statistic apply for non cirrhotics with genotype 3? Now I'm wondering if I should even wait!
Thanks so much Alan
As you can see anything I hear about Gilead / Brisol Meyers it catches my eye. I've relapsed 3 times before completion of any therapy I've been on.
I'm very anxious ( too anxious ) to do it again however no more Interferon / Riba I really do want to wait for the end of trials to do this again but can't help wanting to get this overwith. I really fear resitance to the drugs and getting my hopes up again as well
but thanks for helping me better understand whats been going on
Bill S
Latest news from EASL over the weekend is that the Gilead all oral drugs seem to be very effective for Genotype 2 (up to 98% for those without cirrhosis) but there's a strong relapse rate for Genotype 3 (up to two-thirds of those with cirrhosis and GT 3). They are also using the drug for Genotype 1 but it seems most effective with Peg-int. That will probably be the drug available first as an alternative to the current triple therapy. However, if a person is genotype 1 and can wait for one of the other oral drugs by the end of 2014 or get into a trial, that's probably the way to go. Most of these new oral combinations are showing 80+ percent effectiveness even for prior relapses and cirrhotics. However, just like with the Gilead drugs we need to wait for the full phase 3 data to see if the gains are short-term or have staying power. The AbbVie drugs as well as faldaprevir and daclatasvir all seem to offer real promise for a short 12-24 week therapy with manageable side effects (mainly headache and fatigue). Some new trials are also dropping ribavirin and it's possible that there will be success without resorting to this drug as well (Which is toxic to red blood cells and causes rashes). Good news for the future!
Alan
-- Edited by Freshhope on Monday 29th of April 2013 03:56:53 AM
-- Edited by Freshhope on Monday 29th of April 2013 04:09:12 AM
Thanks Alan
That is so encouraging Thanks for posting that
Bill S
Thanks Alan, gives hope.
Thanks for posting, I would have treated straight away if it wasn't for the fact these drugs are nearly available. Roll on 2014! :D
Correction, I believe Gilead will deliver in early 2014 if they get FDA approval.
The new oral regimens seem to be doing well in further reports from EASL this week. Gilead looks like it will deliver to market in 2013 and be particularly effective for Genotypes 2 and 3. AbbVie reported impressive results Genotype I. 24 weeks post treatment the "cure" rate was 96%! The results for prior non-responders are also very good. However, I'm not sure when they will get approval. Bristol-Myers is close behind, although they have to do a few more trials.
Great news for all!
Alan
http://www.huffingtonpost.com/2013/04/23/hepatitis-c-treatment-cures-abbvie_n_3139989.html